- Home
- RPHM vs XGN Comparison
RPHM vs XGN Comparison
Compare RPHM & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPHM
- XGN
- Stock Information
- Founded
- RPHM 2014
- XGN 2002
- Country
- RPHM United States
- XGN United States
- Employees
- RPHM N/A
- XGN N/A
- Industry
- RPHM Biotechnology: Pharmaceutical Preparations
- XGN Medical Specialities
- Sector
- RPHM Health Care
- XGN Health Care
- Exchange
- RPHM Nasdaq
- XGN Nasdaq
- Market Cap
- RPHM 47.5M
- XGN 49.4M
- IPO Year
- RPHM 2021
- XGN 2019
- Fundamental
- Price
- RPHM N/A
- XGN $2.65
- Analyst Decision
- RPHM Hold
- XGN Buy
- Analyst Count
- RPHM 6
- XGN 1
- Target Price
- RPHM $2.26
- XGN $7.00
- AVG Volume (30 Days)
- RPHM 345.4K
- XGN 24.1K
- Earning Date
- RPHM 11-11-2024
- XGN 11-11-2024
- Dividend Yield
- RPHM N/A
- XGN N/A
- EPS Growth
- RPHM N/A
- XGN N/A
- EPS
- RPHM N/A
- XGN N/A
- Revenue
- RPHM N/A
- XGN $56,660,000.00
- Revenue This Year
- RPHM N/A
- XGN $9.98
- Revenue Next Year
- RPHM N/A
- XGN $13.63
- P/E Ratio
- RPHM N/A
- XGN N/A
- Revenue Growth
- RPHM N/A
- XGN 7.05
- 52 Week Low
- RPHM $1.68
- XGN $1.30
- 52 Week High
- RPHM $92.10
- XGN $3.71
- Technical
- Relative Strength Index (RSI)
- RPHM 18.64
- XGN 39.30
- Support Level
- RPHM $16.10
- XGN $2.64
- Resistance Level
- RPHM $19.00
- XGN $3.03
- Average True Range (ATR)
- RPHM 0.94
- XGN 0.17
- MACD
- RPHM -1.95
- XGN -0.05
- Stochastic Oscillator
- RPHM 0.00
- XGN 1.67
About RPHM Reneo Pharmaceuticals Inc.
Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.